Trials to begin on new Australian COVID-19 vaccine
SA researchers are behind the new DNA vaccine that targets the Omicron variant
A new COVID-19 vaccine developed in SA and administered with a needle-free device is to begin use in human trials.
The DNA vaccine targets the Omicron variant, whereas the Pfizer, AstraZeneca, Moderna and Novavax vaccines target the original strain of the virus.
It was designed by researchers from the University of Adelaide and Basil Hetzel Institute for Translational Health Research at The Queen Elizabeth Hospital precinct.
Being a DNA vaccine means it can be adapted for future variants more easily than the mRNA vaccines, the researchers say.
